Neuraxpharm Arzneimittel GmbH
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Neuraxpharm Arzneimittel GmbH
Neuraxpharm has appoints Viatris’ head of finance in Germany as its new commercial central region officer and country manager to strengthen its position in the German market, while Stada has hired a new head of consumer health in Germany. Meanwhile, the AAM has made multiple key appointments and Hyloris, Siegfried and Mayne Pharma have made top-level additions.
CNS specialist Neuraxpharm has announced expanding its strategic collaboration with Panaxia Labs Israel for advanced medical cannabis-based pharmaceutical products to Poland, after Germany and France. The companies expect sale of the cannabis portfolio to commence in the first half of 2022.
For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.
In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam.
- Generic Drugs
- OTC, Consumer